Nov-13-02 12:19pm

From-LAHIVE & COCKFIELD, LLP

Serial No.: 09/206,132

-5-

Group Art Unit: 1636

T-359 P.07/08 F-264

## REMARKS

## Claim Amendments

Claims 62-63, 71-74, 76-86, and 88-112 were under consideration. Claim 88 has been amended to correct the claim dependency. Accordingly, claims 62-63, 71-74, 76-86, and 88-112 are under consideration. No new matter has been added.

Amendment of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely in order to expedite prosecution. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

## SUMMARY

If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKELELD

Conti, Eso Reg. No. 31,503

Megan E. Williams, Esq.

Registration No. 43,270

Attorney for Applicants

LAHIVE & COCKFIELD, LLP 28 State Street Boston, MA 02109 (617) 227-5941

Dated: November 13, 2002

## APPENDIX A

Version with markings to show changes made to the amended claims:

88. (Amended) The method of claim [61] 62 wherein cells of the tumor are modified in vivo by local administration at the site of the tumor, of a nucleic acid molecule encoding B7-2 in a form suitable for expression of B7-2, to the cells of the tumor.